Zenas BioPharma
James Boylan leads Enavate Sciences and is an accomplished healthcare executive, entrepreneur and innovator with nearly three decades of experience. Mr. Boylan most recently served as President and Head of Investment Banking of SVB Leerink, where he architected and led the transformation of Leerink Swann into an industry-leading health care investment bank that was acquired by SVB Financial in 2019. Across his 12 years at SVB Leerink and prior 12 years as a Managing Director at Merrill Lynch, Mr. Boylan has worked with hundreds of life sciences and biotechnology companies to develop strategy and complete transactions in capital markets and mergers & acquisitions.
Mr. Boylan earned an MBA in finance from the Columbia Business School and a BS in finance from Lehigh University.
This person is not in the org chart
This person is not in any offices
Zenas BioPharma
6 followers
Zenas BioPharma is a cross-border (China-USA-based) biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through its successful business development strategy.